Sexually transmitted diseases (STDs) are a global public health problem. New strategies are needed to combat the growing epidemic. A promising new approach is the development of topical microbicides - safe and effective, female-controlled products designed for intravaginal use and intended to prevent infection at the portal of entry. In this application we propose an integrated program for microbicide development involving three projects and two cores. The program will investigate three groups of carefully selected compounds to determine their in vitro and in vivo effectiveness against important STD pathogens, assess for pertinent toxic properties including genital tract immunotoxicity, and determine whether they are contraceptive. The compounds to be investigate include: (1) sulfated polysaccharides and polymers we have previously shown to be broadly active and essentially non-toxic; (2) a diverse collection of compounds with antimicrobial properties and a history of safe use in humans; and (3) a group of novel compounds not previously investigated as potential microbicides. In Project 1, Drs. Herold and Klotman will examine the in vitro anti-HSV and anti-HIV-1 activity and cytotoxicity of the compounds. This project will make use of primary human cells: vaginal, endocervical and ectocervical cells as well as macrophages and dendritic cells to investigate antiviral activity, mechanism of action and toxicity. In project 2, Dr. Cooper will determine the anti-chlamydial and anti-gonococcal activity of the compounds investigating mechanism of action and toxicity using the human fallopian tube organ culture model. Studies in Projects 1 and 2 will provide important information regarding the spectrum of activity, mechanism of action and cytotoxicity profiles. Based on these data, the most promising compounds will progress to evaluation in Project 3 (Dr. Stanberry), where mouse and guinea pig models of genital tract infection will be used to investigate in vivo activity against HSV and chlamydia. Studies will investigate effects of body fluids (blood or semen) and issues related to female to male STD transmission. Compounds that appear likely to enter clinical trials will be examined in Project 3 to determine whether they adversely effect innate immune responses important in protection of the female genital tract. Other studies in Projects 1 and 2 will isolate heparan sulfate glycosaminoglycans (GAGs) from human genital tract cells and chlamydial elementary bodies and investigate the role of specific GAGs in HSV and chlamydial binding to cells. Core A will provide administrative support. Core B (Dr. Zaneveld) will assess contraceptive and toxic properties (lactobacillus growth, rabbit vaginal irritation, and acute oral toxicity) and prepare formulations. This integrated program will identify and characterize promising microbicides and develop information on new compounds or approaches (GAGs) that will provide future areas for investigation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
7P01AI037940-07
Application #
6407313
Study Section
Special Emphasis Panel (ZAI1-ALR-M (M4))
Program Officer
Savarese, Barbara M
Project Start
1995-09-01
Project End
2004-08-31
Budget Start
2000-09-30
Budget End
2001-08-31
Support Year
7
Fiscal Year
2000
Total Cost
$792,334
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Pediatrics
Type
Schools of Medicine
DUNS #
041367053
City
Galveston
State
TX
Country
United States
Zip Code
77555
Anderson, Robert A; Feathergill, Kenneth A; Chany 2nd, Calvin J et al. (2009) Nitric oxide-dependent human acrosomal loss induced by PPCM (SAMMA) and by nitric oxide donors occurs by independent pathways: basis for synthesis of an improved contraceptive microbicide. J Androl 30:168-82
Milligan, Gregg N; Young, Christal G; Meador, Michael G et al. (2005) Effects of candidate vaginally-applied microbicide compounds on innate immune cells. J Reprod Immunol 66:103-16
Rupp, Richard; Rosenthal, Susan L; Stanberry, Lawrence R (2005) Pediatrics and herpes simplex virus vaccines. Semin Pediatr Infect Dis 16:31-7
Bourne, Nigel; Stegall, Rachael; Montano, Raquel et al. (2005) Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob Agents Chemother 49:1181-3
Keller, Marla J; Tuyama, Ana; Carlucci, Maria Josefina et al. (2005) Topical microbicides for the prevention of genital herpes infection. J Antimicrob Chemother 55:420-3
John, Minnie; Keller, Marla J; Fam, Ehsan H et al. (2005) Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 192:1731-40
Anderson, Robert A; Feathergill, Kenneth; Diao, Xiao-Hui et al. (2004) Contraception by Ushercell (cellulose sulfate) in formulation: duration of effect and dose effectiveness. Contraception 70:415-22
Rupp, Richard; Stanberry, Lawrence R; Rosenthal, Susan L (2004) New biomedical approaches for sexually transmitted infection prevention: vaccines and microbicides. Adolesc Med Clin 15:393-407
Stanberry, Lawrence R; Rosenthal, Susan L; Mills, Lisa et al. (2004) Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. Clin Infect Dis 39:1433-8
Milligan, Gregg N; Chu, Chin-Fun; Young, Christal G et al. (2004) Effect of candidate vaginally-applied microbicide compounds on recognition of antigen by CD4+ and CD8+ T lymphocytes. Biol Reprod 71:1638-45

Showing the most recent 10 out of 40 publications